In its annual report, Novartis lists BAF312's planned regulatory filing date as 2019. Novartis's investigational multiple sclerosis drug cut the risk of disability progression in patients with a tough ...
ZURICH (Reuters) - Swiss drugmakers Novartis and Lonza separately deepened their push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results